Androgen receptor (AR)- and low-density lipoprotein receptor-related protein-1 (LRP1)-positive prostate cancer cell line, LNCaP is more sensitive to emodin than AR-negative LRP-positive prostate cancer cells, PC-3 cells. This evidence concerns the gene AR and prostate cancer.